Abstract
This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.
Keywords: Prostate cancer, PI3K/Akt/mTOR pathway, growth inhibition
Mini-Reviews in Medicinal Chemistry
Title: Involvement of PI3K/Akt Pathway in Prostate Cancer - Potential Strategies for Developing Targeted Therapies
Volume: 5 Issue: 12
Author(s): Nicole Pommery and Jean-Pierre Henichart
Affiliation:
Keywords: Prostate cancer, PI3K/Akt/mTOR pathway, growth inhibition
Abstract: This review presents some therapeutic interventions actually considered in prostate cancer therapy to compensate constitutive activation of the PI3K/Akt signalling pathway induced, particularly, by mutations of PTEN gene. Special emphasis is placed on applicability of EGF-R tyrosine kinase, COX-2, PDK-1, mTOR and farnesyltransferase inhibitors.
Export Options
About this article
Cite this article as:
Pommery Nicole and Henichart Jean-Pierre, Involvement of PI3K/Akt Pathway in Prostate Cancer - Potential Strategies for Developing Targeted Therapies, Mini-Reviews in Medicinal Chemistry 2005; 5 (12) . https://dx.doi.org/10.2174/138955705774933356
DOI https://dx.doi.org/10.2174/138955705774933356 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Indications for Benzodiazepine Antagonist Flumazenil in GABA Mediated Pathological Conditions of the Central Nervous System
Current Pharmaceutical Design Inhibitory Role of Resveratrol in the Development of Profibrogenesis and Fibrosis Mechanisms
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Eker Rat: Establishing a Genetic Paradigm Linking Renal Cell Carcinoma and Uterine Leiomyoma
Current Molecular Medicine Functionalized Upconversion Nanoparticles: Versatile Nanoplatforms for Translational Research
Current Molecular Medicine Future Targets in Endometriosis Treatment: Targeting the Endometriotic Implant
Mini-Reviews in Medicinal Chemistry Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
Current Molecular Medicine Clinical Applications of Gene Therapy in Head and Neck Cancer
Current Gene Therapy Microwave-Assisted Synthesis of Benzo-fused Seven-membered Azaheterocycles
Mini-Reviews in Organic Chemistry Tumor-Targeted Drug Delivery with Aptamers
Current Medicinal Chemistry Increased OPG Expression and Impaired OPG/TRAIL Ratio in the Aorta of Diabetic Rats
Medicinal Chemistry Study of Monocytes/Macrophages Stimuli as the Targets of Treating Inflammatory Bone Diseases
Current Drug Targets In Silico Design of Phenylbenzamide Derivatives Coupled to Pyrimidines as Novel hnRNP K Ligands Against Cancer
Current Bioactive Compounds Recent Advances for the Synthesis of Selenium-containing Small Molecules as Potent Antitumor Agents
Current Medicinal Chemistry Acetylenic Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Lentiviral Vectors: A Versatile Tool to Fight Cancer
Current Molecular Medicine Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery GLP-1 as a Therapeutic Agent in Patients with Type 2 Diabetes Mellitus
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Current Molecular Medicine